Adopt a moratorium on heritable genome editing
Nature 567, 165-168 (2019)
Araki, M. & Ishii, T. Reprod. Biol. Endocrinol. 12, 108 (2014).
Pontin, J. ‘The Genetics (and Ethics) of Making Humans Fit for Mars’ Wired (8 July 2018).
Regalado, A. ‘The DIY designer baby project funded with Bitcoin’ MIT Technol. Rev. (1 February 2019).
Hurlbut, J. B. Nature 565, 135 (2019).
National Academies of Sciences, Engineering, and Medicine. Human Genome Editing: Science, Ethics, and Governance (National Academies Press, 2017).
Costas, J. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 274–283 (2018).
Joy, M. T. et al. Cell 176, 1143–1157 (2019).
Steffann, J., Jouannet, P., Bonnefont, J. P., Chneiweiss, H. & Frydman, N. Cell Stem Cell 22, 481–482 (2018).
Jasanoff, S. & Hurlbut, J. B. Nature 555, 435–437 (2018).
Langlois, A. Palgrave Commun. 3, 17019 (2017).
Burall, S. Nature 555, 438–439 (2018).
Baylis, F. Nature Hum. Behav. 1, 0103 (2017).
Hurlbut, J. B. et al. Trends Biotechnol. 36, 639–641 (2018).
Saha, K. et al. Trends Biotechnol. 36, 741–743 (2018).
Eric Lander (E.L.) notes that institutions with which he is associated — Broad Institute, MIT and Harvard — have interests in CRISPR technology, including patents and patent applications, and that he is a co-inventor on certain patents and patent applications relating to CRISPR-based gene-editing technologies. He also serves on the board of directors for Codiak BioSciences and Neon Therapeutics, and serves on the scientific advisory board of F-Prime Capital Partners and Third Rock Ventures. Feng Zhang (F.Z.) is a founder and scientific adviser for Editas Medicine, Beam Therapeutics, Arbor Biotechnologies, and Pairwise Plants. F.Z. is also an inventor on a number of issued patents and applications relating to CRISPR-based gene-editing technologies. Emmanuelle Charpentier (E.C.) is a co-founder of CRISPR Therapeutics and ERS Genomics and is a member of the scientific advisory board of CRISPR Therapeutics. J. Keith Joung (J.K.J.) has financial interests in Beam Therapeutics, Editas Medicine, Endcadia, EpiLogic Therapeutics, Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the board of directors of the American Society of Gene and Cell Therapy. J.K.J. is a co-inventor on various patents and patent applications that describe gene-editing technologies. David R. Liu (D.R.L.) is a consultant and co-founder of Beam Therapeutics, Editas Medicine, and Pairwise Plants, companies that use genome editing, and is a co-inventor on genome editing patents. Complete financial disclosures are available at https://liugroup.us/david-r-liu/. Wensheng Wei (W.W.) serves as a scientific adviser for EdiGene.